Clathrate Therapeutics Platform

The agency is seeking a vendor to provide a clathrate therapeutics platform. This platform represents a novel system for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. The desired technology must target therapeutic gases to the intended site while minimizing systemic exposure and must be designed for sustained, tunable dosing under physiological conditions. The requested platform aims to separate therapeutic effect from toxicity risk to improve the overall safety margin. The agency requires a versatile platform that is applicable across oncology, cardiovascular, neurological, and regenerative indications. To guide dose and design decisions, the platform must be supported by predictive modeling. The agency requires a partnership-ready architecture that is suitable for integration with drug-device combinations and existing treatment modalities. Only organizations based onshore in the United States are eligible to submit proposals for this opportunity. The selected vendor will perform all work offsite, and the agency is currently looking for budget proposals to determine the cost of the project.